Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation: a Retrospective Study

NCT07817225 is registered in ClinicalTrials.gov with Massimo Falconi as lead sponsor.

NCT NCT07817225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07817225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation: a Retrospective Study
Lead sponsor
Massimo Falconi
Phase
Observational
Overall status
Active, not recruiting
Start date
September 12, 2026
Completion date
December 12, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumor